Furthermore, researchers have demonstrated that the silencing of PVR in melanoma increased sensitivity to combined anti-PD1/CTLA4 therapy, suggesting that targeting PVR could serve as a complement to current immunosuppressive therapies [33]. Here, CTLA4 is linked to melanoma.